As we enter a new era of adjuvant breast cancer therapy where anthracycline–taxane therapy becomes routine for high-risk breast cancer, cumulative doses of anthracycline are below the ceiling ...

Novel biomarkers, such as dysfunctional miRNAs (e.g., miRNA-34a), are closely linked to anthracycline-treated patients. Additionally, human induced pluripotent stem cell-derived cardiomyocytes ...

The AHA has published a scientific statement regarding cardiovascular toxicity in patients with history of treatment for childhood cancer.

Discontinuing therapy generally reduces the symptoms initially, but many patients, especially those who received a greater cumulative anthracycline dose, experience permanent cardiac damage and ...

Developing a new regimen is urgently needed. This phase I study evaluated the maximum tolerated dose (MTD), safety, and efficacy of mitoxantrone hydrochloride liposome (Lipo-MIT) plus cyclophosphamide ...

The relationship between AL and anthracycline cardiotoxicity is unclear. In this large diverse cohort of individuals with cancer, we found that non‐Hispanic Black and Hispanic individuals had a higher ...

Women who spoke with a pathologist about their breast pathology as part of a pilot program reported having better understanding of their tests and feeling empowered in their health care journey ...